ARS Pharmaceuticals came into this earnings season with a bruised stock and a bullish long-term story. The shares are down about 25% over the past month and dropped another 7.4% to US$5.65 in the first full session after the release. The headline this quarter is not the top line. It is the cost base and the margin squeeze that still sits between neffy’s revenue and any path to profit.

Q2 revenue reached US$33.7m, with neffy delivering US$26.2m and a gross margin of about 62%. Yet operating expenses of US$95.1m and rising losses keep the investment debate centered on how quickly ARS Pharmaceuticals can tighten those margins and protect its cash of US$143.8m.

Is ARS Pharmaceuticals a mispriced growth story, or a stock that deserves its beaten down share price given its TTM losses and cash burn risk? Compare the current US$5.65 level to our detailed valuation analysis for ARS Pharmaceuticals.

Q2 2026 Earnings Summary

• Revenue (TTM to Q2 2026): US$438.0m vs. US$306.5m (TTM to Q2 2025) (revenue increased 43%)
• Net Loss (TTM to Q2 2026): US$512.0m vs. US$315.0m (TTM to Q2 2025) (loss widened 63%)
• Basic EPS (TTM to Q2 2026): loss of US$5.21 per share vs. loss of US$3.20 per share (TTM to Q2 2025) (per share loss widened 63%)
• Gross Margin (Q2 2026): approximately 62% for ARS Pharmaceuticals, with year to date margin above 64%. Management highlighted margin pressure from manufacturing inefficiencies and short dated inventory.

Prefer visual charts instead of another wall of earnings tables and raw figures? Get a clear snapshot of ARS Pharmaceuticals’ complete financial picture, including its path toward profitability, in the interactive company report for ARS Pharmaceuticals.

Evaluating ARS Pharmaceuticals’ Bull Case Against Q2 Milestones

Bulls argue ARS Pharmaceuticals can use neffy’s needle free profile to expand the emergency allergy market, deepen recurring use and move toward profitability without fresh capital. The latest quarter offers mixed but concrete milestones. Neffy reached US$26.2m in Q2 U.S. net product revenue and ARS captured 5% total U.S. share, up from 2.5% a year earlier, with 8% share in its targeted prescriber universe and more than 16,000 unique prescribers. That supports the claim that prescriber adoption is broadening, not just concentrated in a few high writers.

The cost side tells a tougher story. Gross margin near 62% and management’s comfort with a roughly 50% gross to net ratio back the idea of a workable unit economics framework. However, Q2 operating expenses of US$95.1m and the need for a greater than 40% cut in cash based SG&A underline that the “self funded scale up” thesis still depends on disciplined execution rather than being proven.

Compare whether that prescriber traction and 62% gross margin story lines up with institutional expectations. See the consensus price target analysis for ARS Pharmaceuticals to check how Wall Street is framing ARS Pharmaceuticals after this earnings move.

ARS Pharmaceuticals Bears See Coverage And Concentration Risks Confirmed

The core bearish worry for ARS Pharmaceuticals is that a single product, neffy, sits on shaky footing because payer coverage, pricing power and cash needs could cap the upside. Q2 results and the July coverage news give that view real support. Neffy now accounts for US$26.2m of net product revenue, yet remains the only commercial asset while ARS-2 is still in a Phase IIb trial that has slipped from late 2026 to Q1 2027. That leaves the business more exposed to any neffy stumble.

Bears also flagged payer pressure and gross to net risk. Management is “comfortable” at roughly 50% gross to net, but the July 1 cycle delivered zero new major commercial formulary wins and triggered a securities probe over prior coverage projections. Combined with heavy SG&A in Q2 and a share price that has fallen about 24% over 90 days, the milestone on improved payer traction was clearly missed.

After volatile trading, heavy SG&A and coverage questions, are these issues isolated or early signals of deeper structural problems? Review our risk analysis for ARS Pharmaceuticals which shows 1 important warning sign.

Stay Ahead With Simply Wall St

If the neffy margin squeeze and ARS Pharmaceuticals’ recent share price pullback have your attention, register for free with Simply Wall St and add the stock to your Watchlist to monitor its price against fair value and watch for a better entry point. After you own ARS Pharmaceuticals or any other stock, use the Portfolio Command Center to cut through noise and focus on key events, valuation changes and fundamental updates that matter. For a broader view, join the Community to see how other investors are thinking about catalysts, risks and turning points. That way you can spot potential opportunities and problems early and stay ahead of the market.

Seeking Alternatives Beyond ARS Pharmaceuticals?

Fresh ideas move first. Stocks with early breakout momentum often get re-rated before most investors even notice. Scan these focused shortlists while the data still matters and get in early.

• Hunt for cash rich companies quietly building strength with the curated list of solid balance sheet and fundamentals stocks (50 results) before the crowd catches the next wave of steady compounders.
• Track where real income meets resilience by reviewing 10 dividend fortresses while yields and coverage are still holding up and before prices move away from attractive entry levels.
• Ride the structural shift toward electrification with 38 power grid technology and infrastructure stocks as grid upgrades accelerate and infrastructure stocks move from under the radar for now to firmly in focus.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.